Navigation Links
Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology

line). Additionally, the percent of "responders" - those who had a 50 percent or greater reduction in seizure frequency - was significantly greater for the 900 and 1,200 mg groups than placebo (32 and 33 percent vs. 16 percent, respectively).

The double-blind study involved 73 centers in 19 countries (Europe, Australia and the United States), and included 396 patients who were 16 to 70 years of age with partial-onset seizures refractory to current treatment. After an initial 8-week baseline period, patients were randomly assigned to receive retigabine (600, 900 or 1,200 mg/day) or placebo, while maintaining their current therapies. Dosing of retigabine was increased gradually over a period of 8 weeks and then maintained for an additional 8 weeks.

It is currently estimated that 30 percent of those affected by epilepsy are not adequately controlled by existing medications. Retigabine is believed to act primarily by opening neuronal potassium-channels resulting in a hyperpolarizing shift that modulates the excitability of the neuronal cells. This mechanism of action (MOA) is different than other antiepileptic drugs.

Retigabine is an investigational compound that has not been found by the Food and Drug Administration (FDA) or any other regulatory agency to be safe or effective in the diagnosis, mitigation, treatment or cure of any disease or illness. It may not be sold or promoted in the United States unless and until the FDA has approved a New Drug Application. Similar restrictions apply in other countries.

About RESTORE

Retigabine is currently being investigated in the Retigabine Efficacy and Safety Trials for Partial Onset Epilepsy (RESTORE), two large, pivotal Phase 3 trials that will evaluate the safety and efficacy of retigabine in refractory epilepsy patients who are receiving one, two or three antiepileptic drugs (AEDs).

At the completion of these trials, retigabine will have been studied in more than 1,300 patients, mor
'"/>




Page: 1 2 3

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... , April 26 e-MDs, an industry leader ... and practice management (PM) solutions, announced they have been selected ... Alaska EHR Alliance (AEHRA).   e-MDs was identified through ... Alaska healthcare providers looking to incorporate an EHR in ...
... 26 Sirion Therapeutics, Inc., a privately held ophthalmic ... is now commercially available.  Zirgan™, which was approved by the ... is a topical ophthalmic antiviral indicated for the treatment of ... , , ...
Cached Medicine Technology:Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 2Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 3Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 4Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3
(Date:7/10/2014)... decades, health-conscious people around the globe have taken antioxidant ... was one of the paths to good health and ... of antioxidant supplements have repeatedly dashed the hopes of ... risk. Virtually all such trials have failed to ... in several trials antioxidant supplementation has been linked with ...
(Date:7/10/2014)... could prove useful in treating small cell lung cancer - ... the Cancer Research UK Manchester Institute, based at The University ... teamed up with experts at AstraZeneca, as part of a ... as AZD3965 - on small cell lung cancer cells. , ... , also helps identify which patients are most likely to ...
(Date:7/9/2014)... sudden, acute episodes of low back pain are not ... pressure, wind direction and precipitation. Findings published in ... American College of Rheumatology (ACR), indicate that the risk ... speed or wind gusts, but was not clinically significant. ... nearly everyone experiences low back pain at some point ...
(Date:7/9/2014)... After Susan Wakulich was told she had an aneurysm, ... ahead of her. , "I was devastated," said Wakulich, who ... "I knew this was a serious diagnosis. Then I met ... that involved a less invasive procedure. It was something I ... participating in a multi-center U.S. clinical trial to evaluate the ...
(Date:7/9/2014)... the metabolism of stromal support cells and immune cells ... cell types in the development of diseases could ... cancer. That was the conclusion of a review article ... leading journal Nature . , Prof. Peter Carmeliet: ... The metabolism of cancer cells has been examined in ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2
... difficile Inpatients on Any One Day; Patients,Dispersed Across ... The life-threatening,bacterium that causes diarrhea and more serious ... than previously,estimated, according to a new study released ... and Epidemiology (APIC)., "The National Prevalence Study ...
... web site by pilots, for pilots, www.wings4aviators.com , custom-embroiders U.S. ... To honor veterans, the company is donating 10% of the proceeds ... 501(c)(3) charity. , ... Hartland, WI (PRWEB) November 11, ...
... nursing, The Magnet Prize, was awarded to Abington Memorial Hospital (AMH) for ... Lake City, UT. This was the sixth year the award was ... ... the most prestigious awards in nursing, The Magnet Prize, was awarded to ...
... to helping seniors and their families understand their Medicare benefits ... hosting eight "Knowing Your Medicare Benefits for 2009" comparison presentations ... ... Torrance, CA (PRWEB) November 11, 2008 ...
... recognized as one of the top performing California physician groups by ... is one of only four California Physicians groups in the greater ... ... (PRWEB) November 11, 2008 -- This is the fifth straight year ...
... unveils TX11: a mobile computing cart designed to accommodate most laptop ... ... -- The Columbus, OH based medical product developer, Artromick, announced that ... mobile computing carts : the TX11 Medserver. While all Artromick ...
Cached Medicine News:Health News:Intestinal Infection Afflicts 13 of 1,000 Hospital Patients, Infection Rates 6.5 - 20 Times Greater Than Previous Estimates, New Study Says 2Health News:Intestinal Infection Afflicts 13 of 1,000 Hospital Patients, Infection Rates 6.5 - 20 Times Greater Than Previous Estimates, New Study Says 3Health News:New Web Site Offers Shirts with Custom-embroidered Aviator Wings for Veteran Military Pilots, Supports Families of the Wounded Fund 2Health News:New Web Site Offers Shirts with Custom-embroidered Aviator Wings for Veteran Military Pilots, Supports Families of the Wounded Fund 3Health News:New Web Site Offers Shirts with Custom-embroidered Aviator Wings for Veteran Military Pilots, Supports Families of the Wounded Fund 4Health News:Abington Memorial One of Just Six Hospitals in the U.S. to Win Magnet Prize 2Health News:Abington Memorial One of Just Six Hospitals in the U.S. to Win Magnet Prize 3Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 2Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 3Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 4Health News:HealthCare Partners Rated A 'Top Performing California Physician Group' By IHA For the Fifth Straight Year 2Health News:HealthCare Partners Rated A 'Top Performing California Physician Group' By IHA For the Fifth Straight Year 3Health News:Mobile Computing Carts Leader to Release New Clinical Computer Cart 2
Mac Pherson titanium tying forceps are ergonomic, very thin, angled with tying platforms. Round ergonomic design for great balance and feel. Fine platforms excellent for tying 10-0 suture....
Fine tying forceps, standard with smooth jaws. For 7-0 to 9-0 sutures....
Harms tying forceps, standard, straight with smooth jaws. For 7-0 to 9-0 sutures....
Tennant stainless steel tying forceps is extra delicate, straight with smooth jaws, 6 mm long platform, round handle with guide pin. For 9-0 to 11-0 sutures....
Medicine Products: